Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Clinical impact of an accurate genetic characterisation of older AML patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.18
Views: 610

Prof Alessandro Rambaldi - University of Milan, Milan, Italy

Prof Alessandro Rambaldi speaks to ecancer at ASH 2018 about the randomised trial looking into the impact of an accurate genetic characterisation of AML patients over 60 years old.

He explains that this characterisation is particularly important in order to identify the secondary AML and the specific mutations that come with this sub group of patients.

Prof Rambaldi also explains the opportunity to identify the sub group of patients who, despite their advanced age, may benefit from the stem cell transplant.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation